Cartherics’ Chief Operating Officer, Dr. Ian Nisbet recently presented at the 3^rd ANZ Biologics Festival at Crown Promenade in Melbourne. His presentation titled, ‘Building a Discovery-to-Clinic Company to Exploit the Full Power of Cell Therapies’ provided insights into Cartherics’ innovative approach to clinical manufacturing and cell therapy development.

The 3^rd ANZ Biologics Festival brought together biopharma leaders to advance Australia and New Zealand’s biologics industry through innovation partnerships and manufacturing expansion.

Dr. Nisbet commented: “the ANZ Biologics Festival was an excellent opportunity to showcase Cartherics’ bold plans to develop a range of cell-derived products to benefit patients with cancer and other intractable diseases.”

Cartherics’ lead product candidate, CTH-401 is the world’s first TAG-72 CAR-NK cell therapy for ovarian cancer, set to enter the clinic later this year.

Dr Nisbet’s presentation discusses:

• Cartherics’ cell therapy platform that enables the rapid development of a diverse range of products and immune cell types
• The potential to leverage extracellular vesicles (EVs) derived from Cartherics’ immune cells
• CTH-401’s proven efficacy against ovarian cancer in mice
• Cartherics’ in-house manufacturing process for CTH-401
• Expansion into non-oncology applications

View the presentation here: https://cartherics.com/wp-content/uploads/2025/02/ANZ-Biologics-Festival-04Feb25_FINAL.pdf